{"certainAgreement":{"piSponsorEmployee":false,"restrictionType":"LTE60","restrictiveAgreement":true},"limitationsAndCaveats":{"description":"Patient enrollment was stopped prematurely due to the drug manufacturer's decision to terminate the development of the study drug, Linsitinib. The study did not proceed to Phase II portion of the study protocol."},"pointOfContact":{"email":"Suzanne.Trudel@uhn.ca","organization":"University Health Network - Princess Margaret Cancer Centre","phone":"416-946-4501","phoneExt":"4566","title":"Dr. Suzanne Trudel"}}